IBD Bioresource

Principle Investigator:
Dr Anton Gunasekera

The Inflammatory Bowel Disease BioResource: Progressing from Genetics to Function and Clinical Translation in Crohn's Disease & Ulcerative Colitis.

The IBD BioResource is being set up by the UK IBD Genetics Consortium and the NIHR BioResource to collect DNA and serum samples from a cohort of 25,000 individuals with Crohn’s disease or ulcerative colitis.

By gaining more information on the genes involved in Crohn’s disease and ulcerative colitis and by understanding the differences in their function and integrating information regarding environmental influences including the microbiota we hope to gain insights regarding causal mechanisms, potential new therapies and treatment approaches for IBD to reduce the burden of disease, and begin to think about a cure.

TIP Trial

Principle Investigator:
Dr Debrata Majundar

Targeting the intestinal immune system in digestive disease. Observational study sampling peripheral blood, intestinal tissue, mucous and faeces from healthy patients, or those with inflammatory bowel disease (IBD) or gastrointestinal cancers. Patients undergoing diagnostic endoscopy or gastrointestinal surgery with IBD or gastrointestinal cancers.

UK-AIH

Principle Investigator:
Dr Debabrata Majumdar

The United Kingdom Autoimmune Hepatitis Cohort (UK-AIH)

The aim of this study is to understand the mechanistic basis of unmet need in autoimmune hepatitis and provide a platform for therapeutic advance.

This shall be achieved by building a UK-wide cohort of people with AIH with willing participants consenting to be contacted for follow up data and participation in future observational studies and clinical trials.

Any patient with a diagnosis of AIH is eligible to join this study.

The UK-PBC Genetics Study

Principle Investigator:
Dr Anton Gunasekera

The primary aim of this study is the identification of genetic variants associated with primary biliary cholangitis (PBC, formerly known as primary biliary cirrhosis).

Some of the secondary aims are identification of genetic variants associated with PBC subgroups such as pruritus and sever fatigue and identification of patients who might be suitable for clinical trials based on their genetic and phenotypical characteristics.

Patients with a diagnosis of PBC based on two of the following three criteria are eligible for this study:

  • A positive test for anti-mitochondrial antibody (AMA);
  • Abnormal liver biochemistry (LFT);
  • Liver histology consistent with PBC;
UK-PSC

Principle Investigator:
Dr Anton Gunasekera

A UK collaborative study to determine the genetic basis of Primary Sclerosing Cholangitis (UK-PSC)

The primary aim of this study is to identify genetic and clinical factors which contribute to the development and outcome of Primary Sclerosing Cholangitis with willing participants consenting to be contacted for follow up data and to participate in future observational studies and clinical trials.

All adults with a diagnosis of PSC are eligible to join this study.